Allogene Therapeutics, Inc. (ALLO) vs Arvinas, Inc. (ARVN)
- Allogene Therapeutics, Inc. ALLO 1.32 −5.71%
- Arvinas, Inc. ARVN 7.14 −4.16%
Allogene Therapeutics, Inc. and Arvinas, Inc. are both Biotechnology companies. Allogene Therapeutics, Inc. and Arvinas, Inc. are of similar size ($504.4M and $499.6M). Allogene Therapeutics, Inc. has negative trailing earnings, so its P/E is not meaningful; Arvinas, Inc. trades at 57.3×. Allogene Therapeutics, Inc. grew revenue faster over the last twelve months: 7,613.1% against −15.1%. Arvinas, Inc. has the higher net margin (2.94% vs −3,517.4%) and the higher return on invested capital (0.00% vs −108.8%). Across the 17 metrics below, Arvinas, Inc. leads on 11 and Allogene Therapeutics, Inc. on 6.
Valuation
Profitability
| Metric | ALLO | ARVN | Biotechnology median |
|---|---|---|---|
| Gross margin | 100.00% | 97.16% | 65.16% |
| Operating margin | (3,832.45%) | (5.72%) | 0.00% |
| Net margin | (3,517.41%) | 2.94% | 0.00% |
| Free cash flow margin | (2,180.62%) | (65.93%) | 0.00% |
| Return on equity | (42.39%) | 1.59% | (56.66%) |
| Return on assets | (32.43%) | 1.17% | (49.22%) |
| Return on invested capital | (108.81%) | 0.00% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack